What Are the Most Common Rabeprazole Side Effects?

Rabeprazole sodium for injection is used for bleeding of gastric and duodenal ulcers, which is not suitable for oral therapy. This product is for patients who are not suitable for oral rabeprazole. Rabicip iv can be used: 1. Sequential inertial therapy of oral rabeprazole, for example, patients who previously took this product and now cannot take it for some reason; 2. Hemorrhagic or erosive active duodenal ulcer; 3. Hemorrhagic or erosive active gastric ulcer; 4. Short-term treatment of corrosive and ulcerative gastroesophageal reflux disease (GERD); 5. Preventing acid increase; 6. Acute treatment of severe mucosal injury; -Ehrlich syndrome. ^[1] .

Rabeprazole sodium for injection

Rabeprazole sodium for injection is used for bleeding of gastric and duodenal ulcers, which is not suitable for oral therapy. This product is for patients who are not suitable for oral rabeprazole. Rabicip iv can be used: 1. Sequential inertial therapy of oral rabeprazole, for example, patients who previously took this product and now cannot take it for some reason; 2. Hemorrhagic or erosive active duodenal ulcer; 3. Hemorrhagic or erosive active gastric ulcer; 4. Short-term treatment of corrosive and ulcerative gastroesophageal reflux disease (GERD); 5. Preventing acid increase; 6. Acute treatment of severe mucosal injury; -Ehrlich syndrome. ^[1]

Chemical Name of Rabeprazole Sodium: 2-[[[[4- (3-methoxypropoxy) -3-methyl-2-pyridyl] -methyl] sulfinyl] -1H-benzimidazole Chemical structure of sodium: http://x1.webres.medlive.cn/drugref/ChemPreparationDetail/201409021129520538.jpg
Molecular formula: C ₁₈ H ₂₀ N ₃ NaO ₃ S
Molecular weight: 381.43

Rabeprazole sodium for injection is a white or off-white loose, lyophilized block or powder.

It is used for bleeding of gastric and duodenal ulcers that are not suitable for oral therapy. This product is for patients who are not suitable for oral rabeprazole. Rabicip iv can be used:
1. Sequential inertial therapy of oral rabeprazole, for example, patients who have previously taken this product orally and cannot take it for any reason now
2. Hemorrhagic or erosive active duodenal ulcer;
3. Hemorrhagic or erosive active gastric ulcer;
4. Short-term treatment of corrosive and ulcerative gastroesophageal reflux disease (GERD);
5. Prevent acid increase;
6. Acute treatment of severe mucosal injury;
7. Zhuo-Ellison syndrome.

20mg

Recommended for intravenous injections when oral administration is not possible. You can stop the injection when you take it orally. The recommended dose is one bottle (20 mg) daily. Parenteral administration other than injection is not allowed.
Injection: Before injection, the drug must be dissolved in 5ml of sterile water for injection for 5-15 minutes.
Instillation: The solution must be further diluted and instilled within 15-30 minutes.
Compatibility with various injections: This product is soluble in glucose injection, glucose sodium chloride injection.
Dosage for different populations: elderly patients, patients with renal impairment, and patients with mild to moderate liver injury do not need to adjust the dosage. Use of rabeprazole sodium in patients with mild to moderate liver damage can increase exposure and reduce elimination. There is no clinical data on the use of rabeprazole sodium in patients with severe liver injury, and it is recommended that such patients be used with caution.
Rehydration: This product needs to be injected with 5ml of water for injection.
The solution should be used within 4 hours after preparation. Discard the unused part. For injectable drug mixtures, supplements or further diluted solutions, check for changes in color, sedimentation, clarity, leaks, etc., and discard unused parts.
PH after rehydration: 8.5-10.5.

According to foreign literature:
1. Serious side effects:
(1) Shock: It has been reported that this product has allergic and shock side effects, so if you find any abnormalities, stop taking it immediately and handle it properly.
(2) Blood: This product rarely causes various types of blood cell reduction, platelet reduction, granulocyte deficiency, hemolytic anemia, etc. However, it may cause granulocytopenia, anemia, etc. If abnormality is found, stop taking it immediately and treat it.
(3) Visual impairment: There are reports of visual impairment when taking this medicine abroad.
2. The most common adverse reactions were headache, diarrhea, and nausea. Other adverse reactions are rhinitis, abdominal pain, weakness, flatulence, pharyngitis, vomiting, non-specific pain or back pain, dizziness, flu symptoms, infectious cough, constipation, and insomnia.
3. Adverse reactions include pruritus, rash, palpitations, myalgia, chest pain, dry mouth, indigestion, hypersensitivity of nerves, lethargy, bronchitis, sinusitis, chills, belching, leg convulsions, urinary tract infections, arthritis and fever , Limb weakness, numbness, decreased grip strength, unstable walking, and tiredness.
4. Rare adverse reactions should be: anorexia, gastritis, weight gain, depression, pruritus, visual / olfactory dysfunction, stomatitis, sweating and leukocytosis.
Liver enzymes increased in 5.2% of patients, such as ALT, AST, AI-P, -GTP, and LDH.
6. There have been reports of herpes or other skin reactions including erythema. Discontinue treatment immediately when skin lesions occur.

1. Prohibited if you are allergic to rabeprazole sodium, benzimidazole or any of the ingredients in the prescription. 2. Banned for pregnant and lactating women.

1. Symptomatic response to treatment with rabeprazole sodium does not exclude the presence of gastric or esophageal cancer. Therefore, the possibility of cancer should be ruled out before starting treatment with this product. Although no obvious drug-related safety issues were seen in age- and sex-matched patients with mild-to-moderate liver injury and normal subjects, doctors advised that special attention be given to patients with severe liver injury when first treated with this product.
2. When taking this product, blood tests and blood biochemistry (such as liver enzyme tests) should be performed regularly. If abnormalities are found, the drug should be stopped and processed in a timely manner.
3. Use with caution in patients with liver damage.

Pregnant and lactating women are prohibited.

Safety to children has not been determined (no experience with use).

This medicine is mainly metabolized by the liver. Generally, elderly people have poor function and will cause side effects. If severe side effects occur, the drug should be suspended.

Rabeprazole sodium is metabolized in the P450 (CYP450) drug-enzyme system. Studies in healthy people show that there is no clinically significant interaction between rabeprazole sodium and other clinically metabolized drugs in the CYP450 system, such as warfarin and theophylline (single-dose oral), diazepam (single intravenous injection) and phenytoin (Single intravenous injection, supplemented orally).

Rabeprazole is a benzimidazole-based compound and a second-generation proton pump inhibitor. It is the last step to block gastric acid secretion by specifically inhibiting gastric wall cells H +, K + -ATPase system. The effect is dose-dependent, and both the basal gastric acid secretion and the gastric acid secretion in the stimulated state can be suppressed. Olgamin sodium for injection has no antagonistic effect on choline and histamine H2 receptors.